Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

The global burden of atopic dermatitis (AD) in older adults is considerable and is expected to continue increasing to 2050.

Atopic dermatitis—the most common type of eczema—can look very different on darker skin tones. As someone living with the ...

Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma ...

Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model ...

A newly developed Naples Pediatric Food Allergy grading scale, incorporating clinical history and examination, shows promise in streamlining the diagnosis of food allergies in children, potentially ...

Rosacea was consistently diagnosed correctly from images, while atopic dermatitis and squamous cell carcinoma proved more ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...